The company's focus is on RT-114 due to capital constraints, using RT-116 as a discovery program. They have budgeted for Phase 1 trials and aim for competitive costs. RT-114 shows less weight loss variability than PG-102 injections, suggesting better results for patients.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing